711 HBM1022, a novel anti-CCR8 antibody depletes tumor-infiltrating regulatory T cells via enhanced ADCC activity, mediates potent anti-tumor activity with Keytruda

Similar Items

• Pembrolizumab (Keytruda) in blockade of PD-1 Pathway to enhance tumor immunity in Oral squamous cell carcinoma
  by: P. Kowsalya
  Published: (2024-06-01)
• Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda®
  by: Jakob C. Stüber, et al.
  Published: (2024-09-01)
• Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial
  by: Michael Lee, et al.
  Published: (2024-10-01)
• Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.
  by: Hasan Alsaid, et al.
  Published: (2017-01-01)
• ESA1022 – PENGKOMPUTERAN KEJURUTERAAN AEROANGKASA. MEI 2006
  by: PPKA, Pusat Pengajian Kejuruteraan, Aeroangkasa
  Published: (2006)